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SunllTlary 
Human histocompatibility leukocyte antigen (HLA)-DM is a facilitator of antigen presentation 
via major hlstocompatibility complex (MHC)  class II molecules.  In the absence of HLA-DM, 
MHC  class II  molecules  do not present  natural peptides,  but  tend to  remain associated with 
class II-associated invariant chain peptides  (CLIP).  Recently,  DM was shown to catalyze the 
release of CLIP from HLA-DR. We have investigated which peptides bound to HLA-DR are 
vulnerable to release upon encountering DM. By directed substitution of allele-specific anchor 
residues between  CLIP  and DR3-cognate  peptldes  and  the  application  of recombinant DM 
we show that DM catalyzes the release of those peptides bound to HLA-DR3 that do not have 
appropriate anchor residues and, hence, no optimal ligand binding motif. Thus, HLA-DM acts 
as  a peptide  editor,  facilitating selection  of peptides  that  stably bind to  class II  molecules for 
eventual presentation to the immune system from the pool of available peptides. 
M 
HC  class II molecules are heterodimeric transmem- 
brane glycoproteins that present peptides to CD4 Th 
cells (1, 2). HLA-DR, a prototype class II molecule, usually 
presents peptides derived from exogenous sources. After as- 
sembly of the MHC class II ot[~ dimers in the endoplasmic 
reticulum  (ER),  the  complex associates with the invariant 
chain  (Ii) (3).  Subsequently,  the ci[3-Ii complex is targeted 
to specialized antigen-processing (MIIC)  vesicles that con- 
tain  antigens  gathered by endocytosis  (4,  5).  Ii is  sequen- 
tially degraded,  allowing class II molecules to bind exoge- 
nous peptides in the MIICs.  One  of the final biosynthetic 
intermediates  in  the  degradation  of Ii  is  the  complex be- 
tween  oti3DlZL and  class II-associated  invariant  chain  pep- 
tide  (CLIP),  which  represents  a  nested  set  of  Ii-derived 
peptides that bind in the groove of the class II complex. In 
vitro  experiments  show  that  release  of CLIP  requires  an 
acidic pH, which is a feature of endocytic compartments in 
vivo (6-8). 
In  cell lines  mutated  for the  MHC-encoded  HLA-DM 
molecule,  however,  DR3  remains  mainly  complexed  to 
CLIP, indicating failure to release this Ii peptide. Similarly, 
in transgenic mice lacking H2-M, the murine equivalent of 
HLA-DM, the majority of the class II molecules is bound to 
CLIP (9,  10). DM is a nonpolymorphic, 0~-heterodimeric 
complex  located  in  MIIC  compartments  (11-16).  P,.e- 
cently, DM was shown in vitro to catalyze the dissociation 
of CLIP from DR3  (17-19). Thus, DM seems to facilitate 
the  generation  of DR  complexes  that  can  accommodate 
antigenic  peptides.  Besides  CLIP,  DM  is  able  to  release 
some but not aH antigenic peptides from class II molecules 
(17).  We  set  out  to  determine  which  peptide-DR  com- 
plexes  are  preferential substrates for the  catalytic  action  of 
HLA-DM  and  which  factors  determine  this  process.  We 
demonstrate  that  DM  functions  as  a  general  catalyst  for 
peptide  release  from DR.  The  composition of the  bound 
peptide is the crucial factor determining which peptides can be 
released from the class II complex upon encountering DM. 
Materials  and Methods 
Cell Lines and Culture Conditions.  The B ×  T hybnd cell line 
T2.DR3,  a stable derivative  of the T2 cell line transfected with 
HLA-DR3, was kindly provided by P. Cresswell (20) and main- 
tamed in IKPMI supplemented with 5°6, fetal calf serum and 500 
~g/rnl G418 (Sigma, Poole, UK). Sf9 cells (PharMmgen,  San Di- 
ego, CA) were grown In suspension in Grace's medmm (Imperial 
Laboratories, London, UK) supplemented with 10% fetal calf se- 
rum,  1% Amphotencin B  (Sigma), and  50  la,  g/ml  Gentamycm 
(Sigma) at 37°C. 
mAbs and Peptides.  mAb L243 (American Type Culture Col- 
lection,  P,.ockv]lle, MD) binds to a nonpolymorphic determinant 
present on HLA-DR molecules, mAb 5CI was raised against the 
c(1 and 0t2 domains of DMcx as described before (21). The DM[3- 
specific anuserum FS4 was raised by F. Sanderson (Imperial Can- 
cer  Research  Fund,  London, UK)  by immunizing rabbits with 
recombinant DM[3 protein expressed in bacteria. His-tag--specific 
mAb was obtained from Daanova. 
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Volume  184  November 1996 2019-2024 Table  1.  Alignment  of Peptides Accordin,¢ to the HLA-DR3  A  B 
Binding Motif 
Relative position 
Antigen  Sequence  1  4  6  9 
CLIP (81-104) 
CLIP (81-104)  A--+D 
CLIP (89-101) 
CLIP (89-101)  P--+K 
CLIP (89-101) 
A-+D, P--+K 
CLIP (81-92) 
ApoB (2877-2894) 
ApoB (2877-2894)  D--+A 
HAChRo~ (312-325) 
MOMP  (251-265) 
LPKPPKPVSKMRMATPLLMQALPM 
LPKPPKPVSKMRMDTPLLMQALPM 
SKMRMATPLLMQALPM 
SKMRMATKLLMQALPM 
SKMRMDTKLLMQALPM 
LPKPPKPVSKMR 
ISNQLTLDSNIKYFHKLN 
ISNQLTLASNIKYFHKLN 
VRKVFIDTIPNIMF 
QASLALSYRLNMFTP 
Amino acids forming optmial specific contact sites for the HLA-DR3- 
binding groove are indicated  in bold and nonoptimal specific contact 
sites are underlined (23, 29)  Pepndes are referenced in 19, 23, 25, 29. 
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Figure 1.  P.ecombmant  soluble DM. Affinity purified sDM molecules 
were subjected  to PAGE on SDS gels (A), followed by Coomassm blue 
staining (lane C.B ) or Western blotting (lanes a  and [3). Two &fferently 
glycosylated DM0/chains were detected  by the DMc~-speofic mAb 5C1 
(21) (lane or) and the DMIB chain was detected  by a mAb specific for the 
His-tag on the DM~ chain (lane [3)  Molecular  sizes are m&cated on the 
left (in kD). Analysis of purified sDM on a nauve gel (B) was lbllowed by 
Western  blotting using the mAb 5C1 for the DMo~ chain (lane a) or the 
DM[3-speclfiC antiserum FS4 (lane [3), 
Peptides (Table  1) were synthesized on a multiple pepnde syn- 
thesiser  (SMPS  350,  Zinsser  Analytic,  Frankfurt/M,  Germany) 
using Fmoc/tBu  strategy  and Wang resin  (p-benzyloxybenzylal- 
cohol-polystyrene).  NH2-termmal  biotinylation  was  conducted 
during synthesis and pepudes were checked for purity and struc- 
ture as descnbed (25). 
Production and Purification of  HLA-DM and HLA-DR.  Truncated 
genes  coding  for  soluble  DMci  and  DM[3  chains  lacking  the 
transmembrane and the cytosolic regions were generated by poly- 
merase  chain  reaction.  The  genes  were  truncated  after  codons 
244 (DMA) and 274 (DMB) of the original eDNA sequences (13) 
and a hexa-histidine tag (His-tag) was genetically attached to the 
novel COOH  terminus of the DMI3 chain.  The constructs were 
cloned  into  the  dual  promoter  transfer  vector  pBacp10pol(22) 
and recombinant baculoviruses were produced using BaculoGold 
DNA  (PharMlngen).  sDM  was  produced using Sf9 cells in pro- 
tein-free medium (PharMmgen)  to prevent aggregation of the re- 
combinant protein, sDM was purified by atiqmt  T  chromatography 
via the His-tag using TALON metal affinity resin (Clontech, Palo 
Alto,  CA)  in  the  presence  of 1%  detergent  (C12Ev or  NP-40). 
The complex was eluted using a gradient of(1-100 mM mfidazole 
in PBS, pH 8.(I. 
HLA-DR3 molecules were purified from T2.DR3  cells by af- 
fimty purifcation using L243-coupled CNBr-actlvated Sepharose 
(Pharmacla,  Milton  Keynes,  UK),  essentially as  described before 
(23).  The complexes were eluted with 25 mM Na2COj,  0.15  M 
NaCL, 0.1% CI2G,, and (1.1 mM PMSF, pH  11, neutralized with 
50 mM Tris-HC1, pH 8.4,  followed by buffer exchange for PBS 
containing either NP-40 or CleE,~. 
Peptide Dissociation Assay.  The  dissociation  rates  of blotiny- 
lated peptldes  from DR3  were measured  essentially as  described 
(24,  25)  using affimty-punfied HLA-DR3 molecules (25,  26).  In 
brief,  DR3  complexes were  preloaded  with  2  [I,M  blotlnylated 
peptldes for 3 d  (37°C, pH 4.5)  in binding butter containing 0. l% 
NP-4i) or C12E,~, pH 4.5. Excess pepndes were removed by 10-K 
ultrafiltratlon (Amlcon Corp.).  The time course of peptlde disso- 
ciation from the preloaded DR3 complexes was determined dur- 
ing 48  h  at  37°C in binding buffer using  10  nM  of DR3  com- 
plexes in the presence or absence ofS0 nM sDM and an excess of 
50  FtM  unlabeled  ApoB(2877-2894)  (Table  1).  MHC-peptlde 
complexes were imnmnoprecipltated with immobilized L243 and 
pepndes  were  detected via streptavtdm  and  biotmylated peroxl- 
dase  (24,  25).  The  absorbance  at  405  nm  was  measured  by  an 
ELISA reader (Multlskan Plus, Titertek, Meckenhelm, Germany) 
and nonspeclfic signals  (quadruplicates,  typically 15%  of maximal 
absorbance)  were subtracted from the data. 
SDS-PAGE, Native PAGE, and IVestern Blot Analysis.  SDS- 
PAGE of purified sDM was perfbrmed on  12.5% polyacrylamlde 
gels after boiling of the  samples  for 5  mira  in  reducing Laemmh 
sample buffer.  For native PAGE analysis,  samples were incubated 
in non-reducing sample buffer for 30  mm at room temperature. 
Western blot analyses were pertbrmed as described (21). 
Results and  Discussion 
To  study  the  function  of HLA-DM  independent  from 
any  associated  proteins,  recombinant  soluble  DM  (sDM) 
was  generated  using  a  baculovlrus  expression  system.  The 
recombinant matenal was purified via a  His-tag attached  to 
the  DM13  chain,  using  metal  chelate  affinity chromatogra- 
phy.  The  purity  and  composition  of the  isolated  complex 
was assessed by SDS-PAGE and Western blot analyses.  The 
isolated  product  was  highly pure  in  that  it  consisted  solely 
of two  proteins  with  apparent  molecular  masses  of 28kD 
and  29kD  (Fig.  l,  C  and  B)  that  were  confimled  to  be 
DM0~ and DM13 chains,  respectively, using DMa  and DM13- 
His-tag-specific  mAbs  (Fig.  1,  a  and  13). Native  PAGE 
demonstrated  that the sDM was secreted as a heterodimertc 
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Figure 2.  Ability  of sDM to catalyze peptlde dassociatlon from CLIP- 
DR3  complexes containing  or lacking the  NH2-temnnal  fragment of 
CLIP  The timecourse of in vitro dissociation of blotinylated peptides 
bound to isolated DR3 was measured In the presence or absence ofsDM. 
Data shown are denved from a representative set of values of five individ- 
ual expenments. DR3 molecules were preloaded with CLIP(81-104) (A) 
or with CLIP(89-101) (B) (Table 1). Exchange of NP-40 for CI2E9 In the 
assays did not change the outcome of the expenments, indicating that the 
findings were not due to the use of 0.1% NP-40 m the assay. 
complex, recognized by both the DMot and DM[3 antibod- 
ies, without any detectable aggregation. 
The  efficacy of sDM was tested by studying its catalytic 
effect on peptide  exchange  on DR3  in an in vitro peptide 
dissociation  assay  using  DR  molecules  isolated  from  the 
DM-negative cell line T2.DR3  (8). In this cell line, DR3 is 
almost exclusively associated with CLIP facilitating loading 
of exogenous  peptides  onto  the D1K molecules because  of 
the  high  spontaneous  disssociation  rates  of endogenously 
bound CLIP. Recombinant sDM catalyzed the dissociation 
of CLIP from CLIP-DR3  complexes (Fig.  2 A), confirm- 
ing the results ofSloan et al. (19). The catalytic effect could 
still  be  measured  when  sDM  was  applied  in  substoichio- 
metric amounts compared with DR  (1:3 ratio) and with an 
pH  optimum  for  catalysis  ranging  between  4.5-5.5  (data 
not shown). 
It is possible that the CLIP-DR  complex is a preferential 
substrate for DM because of specific features of CLIP. The 
NH~-terminal extension of the CLIP peptide extending from 
the peptide-binding groove of D1k (residues 81-89) has been 
implicated in self-release of CLIP from DR(27,  28). To in- 
vestigate  whether  this  extension  helped  peptide  release  by 
DM  we  preloaded  D1K3  molecules  with  either  CLIP(81- 
104)  or CLIP(89-101),  lacking the  extension  but contain- 
ing  the  complete  groove  binding  region  (Table  1),  and 
studied  the  dissociation  rates  of these  peptides  from DR3 
with  or without  DM.  In the  absence  of DM  the  dissocia- 
tion of CLIP(81-104)  was faster than that of CLIP(89-101) 
(tl/2  ~6.25  and  18  h,  respectively).  The  catalytic  function 
of DM  was  indiscriminate  and  dissociation  rates  for both 
peptides were dramatically increased (tl/,- ~0.16  and  1.25 h, 
respectively)  (Fig 2, A  and B). Thus, in this assay, the gen- 
eral mechanism  underlying  the  catalytic  action  of DM  on 
CLIP  dissociation  is not  dependent  on  the  NH2-terminal 
extension  of CLIP.  Moreover,  DM-enhanced  release  of 
CLIP(81-104)  was  independent  of the  presence  of excess 
CLIP(81-92)  added  in  trans  (data  not  shown),  suggesting 
that  DM  does  not  interact  with  CLIP(81-92)  to  exert  its 
catalytic function.  Taken together with the crystallographic 
data on the CLIP-DR  complex (7), our findings imply that 
there are no obvious features of the CLIP-DR  complex to 
single  it  out  as a  substrate  for DM  in  the  cellular pool  of 
peptide-class II complexes. 
To determine why only some peptide-MHC  complexes 
are substrates for DM(17),  we considered which other fac- 
tors could play a role in the process of DM-mediated pep- 
tide  dissociation  from DR.  The  interaction  between  pep- 
tides  and  class  II  molecules  is  determined  by  the  DR 
groove and the primary sequence  of the peptide.  For natu- 
ral ligands,  the  core  of the  peptide  contains  allele-specific 
contact sites that are used as anchonng residues to the class 
II  groove.  Conventional  antigens  found  associated  with 
HLA-DIK3 typically contain a hydrophobic/aromatic  amino 
acid three to four residues from the NH2 terminus  (at rela- 
tive  position  1;  P1),  a  similar  residue  at  P9,  an  aspartate 
forming  the  Dlk3-specific  contact  site  at  P4,  and  a  polar 
auxiliary anchor at P6. All of these residues anchor in com- 
plementary pockets in Dt<3  (23,  25).  In the case of CLIP, 
the DR-binding motif IS designed for promiscuous binding 
to  different  class  II alleles  via hydrophobic  residues  at Pl 
and  P9.  No  allele-specific  contact  sites  are  present,  since 
these  could jeopardize  binding  to  other  class  II molecules 
(7,  29).  The DM  sensitivity of the ot[~CLIP complex may 
be a reflection of this  difference in binding motif and thus 
DM-mediated peptide release might depend on the degree 
of optimal  interactions  between  peptide  and  DR-binding 
groove. 
To test this hypothesis,  peptide dissociation studies were 
performed  using  a  range  of CLIP  variants  and  antigenic 
peptides  together  with  derivatives modulated  at DR3  an- 
choring positions  (Table  1).  Introduction  of the DR3-spe- 
cific  anchor  Asp  in  CLIP(81-104)  at  P4  led  to  a  stable 
complex between peptide and DR  (hi2  >>48  h)  that was 
no longer sensitive to release by DM  (Fig.  3  A).  Substitu- 
tion  of  PrOll 2  at  P6  for  the  anchonng  residue  Lys  in 
CLIP(89-101),  containing the minimal groove binding re- 
gion,  resulted  only  in  a  minor  increase  in  stability  of the 
peptide-DR  complex  (h/2  ~22  h)  (Fig.  3  B).  Addition  of 
DM still led to a release of the peptide (h/2 ~-3 h)  (Fig. 3  B), 
but  only  half as  efficiently  as  the  unsubstituted  CLIP(89- 
101)  (Fig. 4). Introduction of anchoring residues at both P4 
and  P6  generated  a  stable  CLIP-DR  complex,  and  now 
DM was no longer able to induce  dissociation  of the pep- 
tide  (see  Fig.  3  B).  Conversely,  substitution  of the  DR3- 
specific  anchor  Asp2884 for Ala  at P4  in  the  natural  ligand 
ApoB(2877-2894)  (Table  1), enhancing spontaneous disso- 
ciation  of the  peptide  from  the  DR  complex,  made  the 
previously  insensitive  complex  highly  vulnerable  to  the 
catalytic action of DM (see Fig. 3  C). The HAChlKot(312- 
325)  and  MOMP(251-265)  peptides  bind  DR3  with  a 
high  binding  capacity  (6,  19,  25),  but  contain  suboptimal 
anchoring residues in some positions with HAChRot(312- 
325)  containing  the  least optimal binding motif (Table  1). 
The  spontaneous  dissociation  rate  of both  peptides  from 
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Figure  3.  Abihty  of sDM  to 
catalyze pepnde &ssoc]auon from 
peptide-DR3 complexes depends 
on the primary sequence of the 
pepnde complexes to DR3. The 
tlmecourse  of  dissociation  of 
CLIP(81-104) containing  a I)g3- 
specific anchor at P4 from Dl<3 
was measured m the presence or 
absence ofsDM (A). Effect ofm- 
troducnon  of one  or  two  an- 
chonng  residues  m  CLIP(89- 
101)  CLIP(89-101) P-+K and 
CLIP(89-101) A-+D, P--->K,  re- 
spectively, Table 1) on sDM-cat- 
alyzed peptide &ssoc]atmn from 
DP,3 (B)  Dissociation  of ApoB 
(2877-2894) with and without the DR3-speclfiC anchor Asp at P4 (Table 1) from isolated DP.3 molecules  m the presence or absence ofsDM (C). All 
figures shown are derived  from one representative  experiment  out of five mdiwdual  experiments. 
DR3  was  low,  but  faster for HAChRot(312-325)  than 
for  MOMP(251-265)  (Fig.  4).  The  dissociation  rate  of 
HAChRot(312-325) from DR`3 was sensitive to DM catal- 
ysis,  whereas the more stable MOMP-DI<3 complex was 
mostly resistent to  the  action  of DM  (Fig.  4).  Since  the 
HAChR`~(312-325) peptide contains an Asp at P4, but has 
suboptimal anchors for the other contact sites,  and MOMP 
(251-265) lacks the Asp, but otherwise contains an optimal 
binding motif, these peptides show that the DM sensitivity 
of peptide-DR`3  complexes was  not solely dependent on 
the absence or presence of the DR3-specific anchor. Taken 
together, the data demonstrate that the susceptibility of the 
peptide-DR.3 complex for DM correlated with the overall 
number of positive interactions anchoring the  peptide  to 
the peptide binding groove of DR (Fig. 4; Table 1). 
In conclusion, the  data presented here  imply that  DM 
functions as a general catalyst to dissociate peptides bound 
to DR`3. These data are consistent with the observation of a 
transient interaction between DM and DR`, irrespective of 
loading with  cognate peptide  or CLIP  (21).  The primary 
sequence of the peptide itself seems to be the factor deter- 
mining whether it can be released by DM.  The  comple- 
ment of optimal anchoring residues in the peptide dictates 
the susceptibility of the complex for DM-mediated peptide 
release,  probably by influencing the  stability and free  en- 
ergy  of the  pepude-DR,3  complex.  The  composition of 
the  nonanchoring residues  in  the  pepude  core,  together 
with the regions flanking the core,  may contribute to this 
process in a more subtle manner. 
The  consequence of the  unrestricted action  of DM  is 
that in vivo all peptides bound to DR are submitted to the 
action of DM.  Only the most stably bound peptides, pre- 
sumably selected by a stochastic process, will remain associ- 
ated with the  class  II molecule to be exported to  the  cell 
surface for antigen presentation. Thus, DM  has  an editor 
function (17),  optimizing presentation of appropriate pep- 
tides. One could imagine that peptides containing  less opti- 
mal  anchors  also  reach  the  cell  surface  on  DR.  when 
present in h~gh amounts or by having an intermediate off- 
rate. A role of DM  may be to reduce presentation of these 
v 
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Figure 4.  Effect ofsDM on d]ssocxauon  rates of CLIP variants  and an- 
ngemc pepudes, rather modulated or not at DR3  anchonng posmons, 
from isolated DR.3 complexes, ill2  values of &ssoc]atzon of prebound 
peptldes to DP,.3 molecules  were detemuned from the nmecourse of &s- 
soclatlon of pepude from DP,.3 and represent a mean value of five m&- 
v]dual experiments. Dissociauon was measured m the absence (hatched 
bars) or presence (solid bats) ofsDM. In cases in which a 50% d]ssoclauon 
ofpeptlde from DP,.3 was not reached within 48 h tl/2 values were are &- 
vlded rote two groups denoted as 48 <tl/2 <100 h, and as >>100 h 
pepudes as far as possible. In this scheme, the level of DM 
and DR  in MIIC vesicles of different tissues could be  of 
relevance  for  autoimmune diseases  that  may  depend  on 
presentation of self-peptides with subopnmal anchors (30). 
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